Back

Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April

Oslo, Norway, 19 April 2017 – Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2017 results on Tuesday, 25 April 2017. A presentation by Targovax’s management to investors, analysts and the press will take place in Oslo at 10:00 CET.

 

The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.

 

Presentation

The presentation will take place at 10:00 CET at:

 

Hotel Continental

Stortingsgaten 24/26

0117 Oslo

 

The presentation will also be webcast live and can be accessed through www.targovax.com.

 

Conference call

At 14:00 CET (08:00 EST) the company will host a telephone conference which will include a presentation of the results, following a Q&A session. Targovax’s management will present the company. Call-in details can be found below.

 

Call-in numbers:

Norway Toll-Free Number: 800 19 747

Norway Toll Number: +472350 0559

UK Toll-Free Number: 08082370030

UK Toll Number: +442031394830

US Toll-Free Number: 1866 928 7517

US Toll Number: +1 718 873 9077

 

Access code: 10177309#

Please make sure to dial in at least 5-10 minutes ahead to complete your registration.

See attached list for more dial-in numbers.

http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Access_List.pdf

 

 

For further information, please contact:

Renate Birkeli, Investor Relations

Phone: +47 922 61 624

Email: moc.x1511447730avogr1511447730at@il1511447730ekrib1511447730.etan1511447730er1511447730

 

Media and IR enquires:

Jan Petter Stiff – Crux Advisers (Norway)

Phone: +47 995 13 891

Email: on.xu1511447730rc@ff1511447730its1511447730

 

Julia Phillips/Simon Conway – FTI Consulting (International)

Phone: +44 20 3727 1000

Email: moc.g1511447730nitlu1511447730snoci1511447730tf@xa1511447730vogra1511447730T1511447730

 

 

About Targovax

 

Arming the patient’s immune system to fight cancer

 

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

The Company’s development pipeline is based on two novel proprietary platforms:

The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be a tumor-targeted immune activator. The platform has the potential to generate therapies with superior efficacy and safety compared to the first approved oncolytic virus therapy, Imlygic®, launched by Amgen. We continue to expect key proof of concept data for this platform in 2017 from a clinical study of lead program ONCOS-102 in patients with refractory malignant melanoma.

The second platform, TG peptides (TG), solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations.  The TG platform’s therapeutic potential stems from its ability to enable a patient’s immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical study of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.

Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications. Already promising safety and tolerability data and early signs of clinical response have been demonstrated.

Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, we have other products in early stages of development.

In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


Source: GlobeNewswire Targovax ASA